Year: 2025
Type: article
Abstract: Castleman disease is a term that represents a spectrum of diseases whose driving factors are poorly understood. Increased interest prompted by the Castleman's Disease Collaborative Network has led to a better understanding of classification, which will lead to a better understanding of underlying pathology and best practices. It is essential that this entity be recognized and correctly classified by anatomic classification (unicentric, oligocentric, and multicentric), by histopathology (the gradient of hypervascular to plasmacytic), and by clinical phenotype (NOS, TAFRO, IPL, HHV8-associated, or POEMS-associated). Most of what we know about therapy is from retrospective studies rather than prospective therapeutic trials, but data are emerging through collaboration. The mainstay of therapy for unicentric disease is surgery. For multicentric disease interleukin-6 blockade is essential for the non-POEMS, non-HHV8 multicentric cases, rituximab-based (plus or minus antiviral) therapy for HHV8 associated cases, and IL-6 blockade versus plasma cell directed therapy for the POEMS subtype.
Source: Hematological Oncology
DOI: 10.1002/hon.70065
Institutions: University Hospital of Basel, Mayo Clinic
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4411319019